Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study.
- DOI
- 10.1177/20420986261473013
- Published
- 2026
- Container
- Therapeutic advances in drug safety
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/20420986261473013,
title = {Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study.},
author = {Xue WY and Li X and Li WT and Qin BZ and Wang CZ and Liu T and Wang M},
year = {2026},
journal = {Therapeutic advances in drug safety},
doi = {10.1177/20420986261473013},
url = {https://doi.org/10.1177/20420986261473013}
}RIS
TY - JOUR TI - Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study. AU - Xue WY AU - Li X AU - Li WT AU - Qin BZ AU - Wang CZ AU - Liu T AU - Wang M PY - 2026 JO - Therapeutic advances in drug safety DO - 10.1177/20420986261473013 UR - https://doi.org/10.1177/20420986261473013 ER -
APA
WY, X., X, L., WT, L., BZ, Q., CZ, W., T, L., & M, W. (2026). Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study.. Therapeutic advances in drug safety. https://doi.org/10.1177/20420986261473013
Source records
- pubmed · retrieved 2026-09-25T08:50:45.051Z